What is Abrocitinib studying for moderate to severe atopic dermatitis?

Abrocitinib is being studied to learn about its safety and effects in adults with moderate to severe atopic dermatitis. This research focuses on how the medication works in real-life clinical settings and is sponsored by Pfizer. Participants will help provide important information about the treatment over two years.

Who may be eligible for this atopic dermatitis clinical trial?

Adults aged 18 years or older with moderate to severe chronic atopic dermatitis may be eligible. The study is open to all genders, but participants must be able to follow study procedures and not have conditions preventing Abrocitinib use. Please review eligibility criteria for more details.

Is there any cost to participate in this atopic dermatitis clinical trial?

Study-related care, including the study drug and all trial visits, is provided at no cost. However, personal travel expenses to and from study visits may vary and are not guaranteed to be covered. Participants should plan accordingly for any travel costs.

Actively Recruiting

Age: 18Years +

All Genders

ID05689151

Observational Study of Abrocitinib Treatment in Adults With Moderate to Severe Atopic Dermatitis and Its Real-Life Impact

Led by Pfizer · Updated on 2025-12-08

183

Participants Needed

Research Sites

82 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are studying the safety and effects of Abrocitinib for adults with moderate to severe chronic atopic dermatitis, a long-lasting skin condition causing inflammation, redness, and irritation. The study focuses on real-life use of Abrocitinib to understand its impact and safety in this patient group. Participants must be over 18 years old without medical conditions that prevent using Abrocitinib. All participants will take Abrocitinib tablets once daily and may continue using medicated topical treatments alongside the study drug. The study lasts 24 months, during which participants will visit the clinic approximately five times, roughly once every 4 to 6 months. The study collects observational data to describe the effects and safety of Abrocitinib over this period. Participants will undergo assessments including skin evaluations using tools like the Investigators Global Assessment IGA and Eczema Area and Severity Index EASI. Researchers will monitor symptoms such as itch severity and sleep quality, along with treatment adherence and any side effects. Safety and effectiveness will be reviewed regularly throughout the study and at its end, with ongoing observation of treatment patterns and patient-reported outcomes.

CONDITIONS

Brief Title

A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Patients older than 18 years of age at inclusion
Patients with clinical diagnosis of moderate-to-severe chronic atopic dermatitis eligible for Abrocitinib
Patients who have been informed of the study procedures and have signed consent

You will not qualify if you...

Patients for whom Abrocitinib is contraindicated
Patients unable to follow study procedures or respond to questions due to language, psychological, social, or geographical reasons
Patients not affiliated with the French social security system
Patients deprived of liberty, under guardianship, or unable to provide oral consent
Patients participating in a clinical study assessing a medicinal treatment (registries and observatories allowed)

Research Team

Pfizer CT.gov Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here